Modification patterns for small interfering RNA molecules with high stability and gene silencing activity
Specific modification patterns for siRNA, incorporating 2'-fluoro and 2'-O-methyl nucleotides and phosphothioate linkages, address the stability and activity challenges of siRNA, resulting in enhanced stability and gene silencing efficacy.
Patent Information
- Application Number
- JP2024532428
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-26
AI Technical Summary
The inherent properties of siRNA, such as being polyanionic and vulnerable to nuclease cleavage, hinder their clinical application due to insufficient cellular uptake and rapid clearance, while nucleotide modifications that enhance stability often compromise gene silencing activity.
Development of specific modification patterns for siRNA, including 2'-fluoro and 2'-O-methyl modified nucleotides, and phosphothioate linkages at defined positions in the sense and antisense strands, along with optional 5'-phosphate modifications, to enhance stability and resistance to nuclease digestion without compromising gene silencing activity.
The modified siRNAs exhibit improved stability and resistance to nuclease digestion, maintaining or enhancing gene silencing activity, and potentially reducing off-target effects compared to unmodified counterparts.
Smart Images

Figure 2024543963000014 
Figure 2024543963000015 
Figure 2024543963000016
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of the filing date of International Patent Application No. PCT / CN2021 / 135465, filed December 3, 2021, the entire contents of which are incorporated herein by reference. [Background technology]
[0002] RNA interference (RNAi) is the process of sequence-specific post-transcriptional gene silencing mediated by small interfering RNA (siRNA).In order to achieve desired therapeutic effect, considerable attention has been paid to the ability of affecting RNAi to specifically silence the expression of target genes.
[0003] The challenges faced by siRNA therapeutics are significant. This is because the inherent properties of siRNA, such as polyanionic nature, vulnerability to nuclease cleavage, make clinical application difficult due to poor cellular uptake and rapid clearance. Modification of nucleotides in siRNA molecules has been used to enhance stability and resistance to nuclease cleavage. However, many modifications to siRNA have been found to have a negative effect on their gene silencing activity.
[0004] Therefore, there is an increasing need to develop potent siRNAs with desired stability and gene silencing activity. Summary of the Invention
[0005] The present disclosure is based, at least in part, on the development of specific modification patterns for small interfering RNAs to enhance stability and resistance to nuclease digestion and reduce off-target effects without compromising gene silencing activity.
[0006] Thus, one aspect of the present disclosure features a modified small interfering RNA (siRNA), comprising a sense strand having 19 nucleotides and an antisense strand having 21 nucleotides.The sense strand, the antisense strand, or both may contain one or more phosphothioate (PS) bonds.In some cases, the sense strand and the antisense strand optionally form a double-stranded siRNA with a 2-nucleotide overhang at the 3' end of the antisense strand.
[0007] In some embodiments, the antisense strand contains (i) 7-9 2'-fluoro modified nucleotides, and (ii) 12-14 2'-O-methyl modified nucleotides. For example, the antisense strand may contain 2'-fluoro modified nucleotides at 7 or more of positions 2-12, 14-16, and 18. Alternatively, or in addition, the antisense strand may contain 2'-fluoro modified nucleotides at positions 2 or 3, and 14, and optionally at position 18. In another example, the antisense strand may contain 2'-O-methyl modified nucleotides at 12 or more of positions 1, 2-13, and 15-21. Alternatively, or in addition, the antisense strand may contain 2'-O-methyl modified nucleotides at positions 1, 13, 17, and 19-21. In some cases, the antisense strand may contain a PS bond between positions 1 and 2, between positions 2 and 3, between positions 19 and 20, and / or between positions 20 and 21.
[0008] In some cases, the chemically modified siRNA disclosed herein (e.g., the antisense strand, the sense strand, or both) may further comprise a modified 5'-phosphate. In some examples, the antisense strand comprises a modified 5'-phosphate. In some examples, the modified 5'-phosphate is E-vinylphosphonate or phosphorothiolate.
[0009] In any of the modified siRNAs disclosed herein, the sense strand contains (i) 2-5 2'-fluoro modified nucleotides, and (ii) 11-16 2-O-methyl modified nucleotides. For example, the sense strand may contain 2'-fluoro modified nucleotides at two or more of positions 5 and 7-11. Alternatively, or in addition, the sense strand includes 2'-fluoro modified nucleotides at positions 5 and 7-10, or at positions 5, 7, 9, and 11. In another example, the sense strand may include 2'-O-methyl modified nucleotides at 11 or more of positions 1-6, 8, and 10-19. Alternatively, or in addition, the sense strand includes 2'-O-methyl modified nucleotides at positions 4, 6, and 11-19. In some cases, the sense strand may further include 2'-O-methyl modified nucleotides at positions 8 and 10. In yet another example, one or more of positions 1-3 in the sense strand may include 2'-O-methyl modified nucleotides. Alternatively, one or more of positions 1 to 3 in the sense strand are unmodified. Alternatively, or in addition, the sense strand may contain a 2'-deoxynucleotide, optionally located at position 9. In some cases, the sense strand may contain a PS linkage between positions 1 and 2, between positions 2 and 3, between positions 4 and 5, between positions 5 and 6, between positions 17 and 18, and / or between positions 18 and 19.
[0010] In some embodiments, the antisense strand (top) and the sense strand (bottom) of the modified siRNA disclosed herein can have one of the following formulas: (i)5'-mffmmffmmffmmffmmfmmm-3' 3'-mmmmmmmmmmdffmmmmmm-5', (ii)5'-mmfmfmfmfmmmmfmfmfmmm-3' 3'-mmmmmmmmmffffmfmmmm-5', (iii)5'-mmfmfmfmfmmmmfmfmfmmm-3' 3'-mmmmmmmmmffffmfmrrr-5', (iv)5'-mfmfmfmffmmmmfmfmfmmm-3' 3'-mmmmmmmmmffffmfmrrr-5' (v)5'-mfmffmmffmmmmfmfmfmmm-3' 3'-mmmmmmmmmffffmfmmmm-5', (vi)5'-mfmfmfmfmfmfmfmfmfmmm-3' 3'-mmmmmmmmfmfmfmfmmmm-5', (vii)5'-mfmfmfmfmfmfmfmfmfmmm-3' 3'-mmmmmmmmfmfmfmfmrrr-5'' or (viii)5'-mfmfmfmfmfmfmfmfmmmmm-3' 3'-mmmmmmmmfmfmfmfmrrr-3', In the formula, m represents a 2'-O-methyl nucleotide, f represents a 2'-fluoro nucleotide, d represents a DNA residue, and r represents an unmodified nucleotide.
[0011] In some examples, the antisense strand (top) and the sense strand (bottom) of a modified siRNA disclosed herein can have the following formula: (i)5'-m*f*fmmffmmffmmffmmfm*m*m-3' 3'-m*m*mmmmmmmmdffmmmm*m*m-5', (ii)5'-m*m*fmfmfmfmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffmfmm*m*m-5', (iii)5'-m*m*fmfmfmfmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffm*f*mrrr-5', (iv)5'-m*f*mfmfmffmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmffffm*f*mrrr-5' (v)5'-m*f*mffmmffmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffmfmm*m*m-5', (vi)5'-m*f*mfmfmfmfmfmfmfmfm*m*m-3' 3'-m*m*mmmmmmfmfmfmfmm*m*m-5', (vii)5'-m*f*mfmfmfmfmfmfmfmfm*m*m-3' 3'-m*m*mmmmmmfmfmfm*f*mrrr-5'' or (viii)5'-m*f*mfmfmfmfmfmfmfmmm*m*m-3' 3'-m*m*mmmmmmfmfmfm*f*mrrr-3', In the formula, m represents a 2'-O-methyl nucleotide, f represents a 2'-fluoro nucleotide, d represents a DNA residue, r represents an unmodified nucleotide, and * represents a PS bond.
[0012] In some embodiments, the sense strand of any of the modified siRNAs disclosed herein can be conjugated to a targeting moiety, for example, N-acetylgalactosamine (GalNAc).Also provided herein is the use of any of the modified siRNAs, or pharmaceutical compositions comprising same, for the manufacture of medicaments for use in silencing expression of target genes and treating diseases associated with target genes.
[0013] In addition, the present disclosure also provides a pharmaceutical composition comprising any of the modified siRNAs disclosed herein and a pharma- ceutically acceptable carrier. Such a pharmaceutical composition may be for use in silencing a gene targeted by the siRNA.
[0014] In another aspect, provided herein is a method for regulating gene expression, comprising contacting a cell with any of the modified siRNAs disclosed herein, or a pharmaceutical composition comprising same. In some embodiments, the contacting step can be carried out by administering the modified siRNA or pharmaceutical composition to a subject having a disease associated with the gene of interest.
[0015] The details of one or more embodiments of the disclosure are set forth in the description below. Other features and advantages of the disclosure will be apparent from the following drawings and detailed description of certain embodiments, and from the appended claims. [Brief description of the drawings]
[0016] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which may be better understood by reference to the drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1] Figure 1 shows exemplary modification patterns of small interfering RNA (siRNA). m: 2'-O-methyl. f: 2'-O-fucosyl. The sticks between the nucleotides represent PS internucleotide linkages. PS linkages may be present at either or both ends of the siRNA molecule. [Figure 2A] Figures showing 5'-phosphate modifications and related interference efficacy are included. Figure 2A: Chemical structure of exemplary 5'-phosphate modifications 5'-E-vinylphosphonate and 5'-phosphorothioate. Figure 2B: Bar graph showing improved gene silencing activity of anti-HBx siRNA with 5'-E-vinylphosphonate modification (X32-G25S-PS6-VP) in antisense strand or 5'-phosphorothioate modification (X32-G25S-PS6-5S) in antisense strand compared with siRNA counterpart without 5'-phosphate modification (X32-G25S-PS6). [Figure 2B]Figures showing 5'-phosphate modifications and related interference efficacy are included. Figure 2A: Chemical structure of exemplary 5'-phosphate modifications 5'-E-vinylphosphonate and 5'-phosphorothioate. Figure 2B: Bar graph showing improved gene silencing activity of anti-HBx siRNA with 5'-E-vinylphosphonate modification (X32-G25S-PS6-VP) in antisense strand or 5'-phosphorothioate modification (X32-G25S-PS6-5S) in antisense strand compared with siRNA counterpart without 5'-phosphate modification (X32-G25S-PS6). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] RNA interference or "RNAi" is a process in which double-stranded RNA (dsRNA) blocks gene expression when introduced into a host cell. (Fire et al. (1998) Nature 391, 806-811). Small interfering RNA molecules (siRNAs) are commonly used in RNAi to inhibit the expression of target genes, thereby achieving a desired therapeutic effect.
[0018] siRNA is a double-stranded RNA, an antisense strand, and a sense strand, which contain complementary sequences and form a double-stranded structure. At least a portion of the antisense strand is complementary to a region in the target mRNA for blocking expression of the mRNA via RNAi. Each strand of the siRNA molecule can have 19-23 nucleotides. In some cases, each strand can have a phosphorylated 5' end and a hydroxylated 3' end. In some cases, the antisense strand can have a couple overhanging nucleotides (e.g., 1 or 2). When siRNA is transfected into a cell, it is incorporated into an RNA-induced silencing complex (RISC) that contains the core protein Argonaute (AGO). The siRNA is then unwound into single-stranded RNA, and the antisense strand remains associated with AGO to form an active RISC, while the sense strand is degraded. The antisense strand base pairs with the target transcript (mRNA), and AGO cleaves the target to silence its function (gene expression).
[0019] Although siRNA is a promising therapeutic agent for regulating the expression of target genes to achieve desired therapeutic effects, RNA molecules are generally vulnerable to nuclease digestion in vivo, which impairs their clinical application. Introducing modifications into RNA molecules is a common approach to enhance the stability of RNA therapeutics. However, the position and / or level of modification often affect the gene silencing activity of the resulting siRNA. Therefore, it is of great interest to design appropriate modification patterns of siRNA to enhance stability and / or resistance to nuclease digestion while maintaining desired gene silencing activity. Such modifications can also reduce off-target effects when compared with unmodified siRNA counterparts.
[0020] Thus, in some aspects, provided herein are specific modification patterns of siRNAs (e.g., combinations of specific nucleotide modifications and phosphothioate (PS) linkages at defined positions in both the sense and antisense strands of the siRNA), pharmaceutical compositions comprising such modified siRNAs, and their use for silencing expression of target genes.
[0021] Unless otherwise specified, the position of a nucleotide in a nucleic acid strand (e.g., sense strand or antisense strand) disclosed herein refers to the position from the 5' end of the nucleic acid strand, i.e., the 5'-terminal nucleotide is numbered as position 1.
[0022] I. siRNA modification patterns In some aspects, the present disclosure relates to specific modification patterns of small interfering nucleic acid molecules (siRNAs). Modification patterns refer to modification profiles that include specific nucleotide modifications (e.g., 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, or combinations thereof) at defined positions in the sense and antisense strands, and / or PS linkages at defined positions in the sense and antisense strands. In some cases, the antisense and / or sense strands of any of the modified siRNAs disclosed herein can further include 5'-phosphate modifications, such as those disclosed herein. siRNAs with such modification patterns show similar or better gene silencing activity compared to their unmodified counterparts. Such modified siRNAs are also expected to be more stable and / or resistant to nuclease digestion compared to their unmodified counterparts.
[0023] (A) siRNA molecule: The present disclosure relates to modified siRNA molecules, which are double-stranded RNA that can induce high levels of gene silencing through the RNAi pathway against target gene transcripts, and also have high stability and / or resistance to nuclease digestion.Compared to their unmodified counterparts, such modified siRNAs are expected to be more therapeutically effective.
[0024] The modified siRNA molecule includes a sense strand and an antisense strand, of which the sense strand and the antisense strand have a specific modification pattern. In any of the modified siRNA molecules disclosed herein, the antisense strand may contain 15-30 nucleotides in length, for example, 18-25 or 19-23 nt in length. In one example, the antisense strand includes a 21 nt length. In another example, the antisense strand includes a 23 nt length. The sense strand or a portion thereof is complementary (fully or partially) to the antisense strand or a portion thereof. In some cases, the sense strand has the same length as the antisense strand. In other cases, the sense strand is shorter than the antisense strand (e.g., 1-5 nt (e.g., 1 nt, 2 nt, 3 nt, 4 nt, or 5 nt, etc.)). In that case, the antisense strand may have an overhang (e.g., 1-5 nt) at the 5' end and / or the 3' end.
[0025] In some embodiments, the sense strand contains 19 nucleotides and the antisense strand contains 21 nucleotides. The sense and antisense strands form a double-stranded siRNA molecule, in some cases with a 2-nucleotide overhand at the 3' end of the antisense strand.
[0026] In some embodiments, the antisense strand in the modified siRNA disclosed herein may contain 7-9 (e.g., 7, 8, or 9) 2'-fluoro modified nucleotides and 12-14 (e.g., 12, 13, and 14) 2'-O-methyl modified nucleotides. Alternatively, or in addition, the sense strand in the modified siRNA may contain 2-5 (e.g., 2, 3, 4, or 5) 2'-fluoro modified nucleotides and 11-16 (e.g., 11, 12, 13, 14, 15, or 16) 2'-O-methyl modified nucleotides. Such modified siRNA may further comprise one or more PS linkages in the sense strand and / or the antisense strand.
[0027] In some instances, the antisense strand comprises 21 nucleotides. Such an antisense strand may have 2'-fluoro modified nucleotides at 7 or more of positions 2-12, 14-16, and 18. For example, the antisense strand may have 2'-fluoro modified nucleotides at positions 2 or 3, and at position 14. In some instances, the antisense strand may have 2'-fluoro modified nucleotides at positions 2, 14, and 18. Alternatively, the antisense strand may have 2'-fluoro modified nucleotides at positions 2, 14, and 18. In specific examples, the antisense strand may have 2'-fluoro modified nucleotides at the following positions: (i) 2, 3, 6, 7, 10, 11, 14, 15, and 18; (ii) 3, 5, 7, 9, 14, 16, and 18; (iii) 3, 5, 7, 9, 14, 16, and 18; (iv) 2, 4, 6, 8, 9, 14, 16, and 18; (v) 2, 4, 5, 8, 9, 14, 16, and 18; (vi) 2, 4, 6, 8, 10, 12, 14, 16, and 18; or (vii) 2, 4, 6, 8, 10, 12, 14, or 16.
[0028] Additionally, the antisense strand can have 2'-O-methyl modified nucleotides at 12 or more of positions 1, 2-13, and 15-21. For example, the antisense strand can include 2'-O-methyl modified nucleotides at least positions 1, 13, 17, and 19-21. In specific examples, the antisense strand can have 2'-O-methyl modified nucleotides at the following positions: (i) 1, 4, 5, 8, 9, 12, 13, 16, 17, and 19-21, (ii) 1, 2, 4, 6, 8, 10-13, 15, 17, and 19-21, (iii) 1, 2, 4, 6, 8, 10-13, 15, 17, and 19-21st place, (iv) 1st, 3rd, 5th, 7th, 10th-13th, 15th, 17th, and 19th-21st place, (v) 1st, 3rd, 6th, 7th, 10th-13th, 15th, 17th, and 19th-21st place, (vi) 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, and 19th-21st place, (vii) 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, and 17th-21st place.
[0029] Alternatively, or in addition, the antisense strand may contain a PS bond between positions 1 and 2, between positions 2 and 3, between positions 19 and 20, between positions 20 and 21, or a combination thereof. In specific examples, the antisense strand may have a PS bond between positions 1 and 2, between positions 2 and 3, between positions 19 and 20, and between positions 20-21.
[0030] In some examples, the sense strand of any of the modified siRNAs disclosed herein may comprise 19 nucleotides. Such a sense strand may have 2'-fluoro modified nucleotides at two or more of positions 5 and 7-11. For example, the sense strand may have 2'-fluoro modified nucleotides at positions 5 and 7-10. Alternatively, the sense strand may have 2'-fluoro modified nucleotides at positions 5, 7, 9, and 11. In specific examples, the sense strand may have 2'-fluoro modified nucleotides at: (i) positions 7 and 8, (ii) positions 5 and 7-10, or (iii) positions 5, 7, 9, and 11.
[0031] Additionally, the sense strand of any one of the modified siRNAs disclosed herein may have 2'-O-methyl modified nucleotides at 11 or more of positions 1-6, 8, and 10-19. For example, the sense strand may include 2'-O-methyl modified nucleotides at positions 4, 6, and 11-19. In some cases, the sense strand may further include 2'-O-methyl modified nucleotides at positions 8 and 10. In other examples, the sense strand may include 2'-O-methyl modified nucleotides at positions 1-3. Alternatively, the sense strand may include unmodified nucleotides at one or more of positions 1-3 (e.g., all of positions 1-3). In specific examples, the sense strand may contain 2'-O-methyl modified nucleotides at: (i) positions 1-6 and 10-19; (ii) positions 1-4, 6, and 11-19; (iii) positions 4, 6, and 11-19; or (iv) positions 4, 6, 8, 10, and 12-19.
[0032] Alternatively, or in addition, the sense strand may contain a PS bond between positions 1 and 2, between positions 2 and 3, between positions 4 and 5, between positions 5 and 6, between positions 17 and 18, between positions 18 and 19, or combinations thereof. In some examples, the sense strand may contain a PS bond between positions 1 and 2, between positions 2 and 3, between positions 17 and 18, and between positions 18 and 19. In other examples, the sense strand may contain a PS bond between positions 4 and 5, between positions 5 and 6, between positions 17 and 18, and between positions 18 and 19.
[0033] (B) 5'-phosphate modification In some embodiments, any of the modified siRNAs disclosed herein may further comprise a 5'-phosphate modification in the sense strand, the antisense strand, or both. In some examples, the antisense strand comprises a 5'-phosphate modification, while the sense strand does not comprise such a modification. In some examples, the sense strand comprises a 5'-phosphate modification, while the antisense strand does not comprise such a modification. In some examples, both the antisense strand and the sense strand comprise a 5'-phosphate modification.
[0034] 5'-phosphate modification refers to the substitution of one or more suitable moieties at the 5'-terminal phosphate residue. Examples include, but are not limited to, E-vinyl phosphonate (5'-E-VP), Z-vinyl phosphonate (5'-Z-VP), 5'-methyl phosphonate, 5'-C-methyl analog, and phosphorothioate. In one example, the 5'-phosphate modification is 5'-E-VP. In another example, the 5'-phosphate modification is phosphorothioate. See Figure 2B.
[0035] (C) Other modifications In some embodiments, the modified siRNAs disclosed herein contain only 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, and PS linkages, optionally in the sense strand, without further modifications, as disclosed herein.
[0036] Alternatively, the antisense strand, the sense strand, or both of the modified siRNA may further comprise other modifications, such as sugar modification, nucleobase modification, backbone modification, or combinations thereof.For example, the sense strand may contain 2'-deoxynucleotide.If the sense strand has 19 nucleotides, the 2'-deoxynucleotide may be located at position 9.Such modifications may confer one or more desirable properties, such as enhanced cellular uptake, improved affinity to target nucleic acid, increased in vivo stability, enhanced in vivo stability (e.g., resistance to nuclease degradation), and / or reduced immunogenicity.
[0037] In one example, the modified siRNAs disclosed herein (e.g., in the sense and / or antisense strands) can have modified backbones at positions different from the PS internucleotide linkages, including those that retain a phosphorus atom (see, e.g., U.S. Pat. Nos. 3,687,808, 4,469,863, 5,321,131, 5,399,676, and 5,625,050) and those that do not have a phosphorus atom (see, e.g., U.S. Pat. Nos. 5,034,506, 5,166,315, and 5,792,608). Examples of phosphorus-containing modified backbones include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates, including 3'-alkylene phosphonates, 5'-alkylene phosphonates, and chiral phosphonates, phosphinates, phosphoramidates, including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thionophosphoramidates, thionoalkyl phosphonates, thionoalkyl phototriesters, selenophosphates, and boranophosphates with 3'-5' or 2'-5' bonds.Such backbones also include those with reverse polarity, i.e., 3' to 3', 5' to 5', or 2' to 2' bonds. Modified backbones that do not contain phosphorus atoms are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages. Such backbones include those with morpholino linkages (formed in part from the sugar portion of the nucleoside), siloxane backbones, sulfide, sulfoxide, and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl and thioformacetyl backbones, riboacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones with mixed N, O, S, and CH2 constituent moieties.In some examples, the modified siRNAs disclosed herein do not contain any backbone modifications, except for the PS internucleotide linkages disclosed herein.
[0038] In another example, the modified siRNA disclosed herein (e.g., in the sense and / or antisense strands) comprises one or more substituted sugar moieties. Such substituted sugar moieties can comprise one of the following groups at the 2' position of the substituted sugar moiety: OH, F, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, and O-alkyl-O-alkyl. In these groups, the alkyl, alkenyl, and alkynyl can be substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. The substituted sugar moiety can also comprise a heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving group, reporter group, intercalator, group for improving the pharmacokinetic properties of an oligonucleotide, or group for improving the pharmacodynamic properties of an oligonucleotide, at the 2' position of the substituted sugar moiety. Preferred substituted sugar moieties include those having 2'-methoxyethoxy, 2'-dimethylaminooxyethoxy, and 2'-dimethylaminoethoxyethoxy. See Martin et al., Helv. Chim. Acta, 1995, 78, 486-504.
[0039] Alternatively or additionally, the modified siRNA disclosed herein (e.g., in sense strand and / or antisense strand) comprises one or more modified natural nucleobases (i.e., adenine, guanine, thymine, cytosine and uracil).Modified nucleobases include those described in U.S. Patent No. 3,687,808; The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859; Kroschwitz, JI, ed. John Wiley & Sons, 1990; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; and Sanghvi, YS, Chapter 15, Antisense Research and Applications, pages 289-302, CRC Press, 1993.Some of these nucleobases are particularly useful for increasing the binding affinity of interfering RNA molecules to their target site. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines (e.g., 2-aminopropyl-adenine, 5-propynyluracil, and 5-propynylcytosine; see Sanghvi, et al., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278).
[0040] Alternatively or additionally, the modified siRNA disclosed herein (e.g., in the sense strand and / or antisense strand) can include one or more locked nucleic acids (LNA). LNA, often referred to as access-restricted RNA, is a modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and the 4' carbon. This bridge "locks" the ribose in the 3'-endo (north) conformation that is often found in A-form duplexes. LNA nucleotides can be used in any of the modified siRNAs disclosed herein. In some examples, up to 50% (e.g., 40%, 30%, 20%, or 10%) of the nucleotides in the interfering RNA are LNA.
[0041] (D) Exemplary modification patterns of siRNAs. In some examples, the modified siRNA disclosed herein may have one of the 2'-fluoro and 2'-O-methyl modification patterns in the sense strand illustrated in Figure 1. In other examples, the modified siRNA disclosed herein may have one of the 2'-fluoro and 2'-O-methyl modification patterns in the antisense strand illustrated in Figure 1. In a specific example, the modified siRNA disclosed herein may have one of the 2'-fluoro and 2'-O-methyl modification patterns in the sense and antisense strands illustrated in Figure 1. Such modified siRNA may further include a modification pattern of PS linkages in the sense and / or antisense strands, as also illustrated in Figure 1. See also the formulas of the antisense and sense strands disclosed herein. Formulas that do not show PS linkages or other modifications of the backbone are meant to encompass both strands without backbone modifications and strands with any type of backbone modification.
[0042] Other specific exemplary modified siRNAs are also within the scope of this disclosure and are provided in Examples 1 and 2, below.
[0043] In some embodiments, any of the modified siRNA molecules described herein may be conjugated to a ligand (targeting moiety) or encapsulated in a vesicle that can facilitate delivery of modified siRNA to desired cells / tissues and / or facilitate cellular uptake.Suitable ligands include, but are not limited to, carbohydrates, peptides, antibodies, polymers, small molecules, cholesterol, and aptamers.For example, one or more GalNAc moieties (e.g., tri-GalNAc moieties) may be used as targeting moieties to deliver modified siRNA to liver cells.
[0044] (E) Target gene The modified siRNA disclosed herein is for use in suppressing the expression of a target gene, and the transcript (mRNA) of the target gene comprises a region that is complementary to the antisense strand in the modified siRNA. Thus, the sequence of the antisense strand and the sense strand can be designed based on the mRNA sequence of the target gene. In some cases, the antisense strand can be completely complementary to the target region in the mRNA of the target gene. In other cases, the antisense strand can be partially complementary to the target region in the mRNA of the target gene (e.g., contains one or more mismatches or gaps), as long as the level of complementarity is sufficient to base pair with the target region, which is within the knowledge of those skilled in the art.
[0045] In some embodiments, the target gene of modified siRNA disclosed herein is a pathogenic gene.For example, the target gene can be a pathogenic gene, such as a virus, a bacteria, or a fungus.In other examples, the target gene is involved in disease or disorder, such as cancer, immune disorder (e.g., autoimmune disease), metabolic disorder or disease, cardiovascular disorder or disease, and other genetic disorder or disease.
[0046] In some examples, the modified siRNA silences the expression of a target gene involved in cancer.Exemplary cancer-related target genes include, but are not limited to, HIF1A, HIF2, IGF1R, VEGF, EREG, KRAS, ALK, BRAF, NRAS, STAT3, CDH2, KIFL1, PIK3CA, Src, RAS, RAF, and TP53.
[0047] In some examples, the modified siRNA silences the expression of a target gene involved in fibrosis. Exemplary fibrosis-related target genes include, but are not limited to, HIF1A, HIF1B, HIF2, TGF-β1, and CTGF.
[0048] In some examples, the modified siRNA silences the expression of a target gene involved in a metabolic disease. Exemplary metabolic target genes include, but are not limited to, AGT, ApoC-III, and ApoB.
[0049] In some examples, the modified siRNA silences the expression of a target gene involved in an immune disease (e.g., an autoimmune disease). Exemplary immune disease-related target genes include, but are not limited to, GATA-3, CCR3, TGF-β1, IL-6, TNF-α, IFN-γ, IL-1β, CCL2, and CCL10.
[0050] In some instances, the modified siRNA may target the genome of a virus or the mRNA expressed therefrom, e.g., the genome and / or mRNA of a coronavirus, such as SARS-CoV2. In some instances, the modified siRNA may silence expression of a viral protein, e.g., a Hepatitis B virus protein (e.g., HBx).
[0051] III. Pharmaceutical Compositions Any of the modified siRNA molecules disclosed herein can be formulated into suitable pharmaceutical compositions.The pharmaceutical compositions described herein can further comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions.Remington: The Science and Practice of Pharmacy 20th Ed.(2000) Lippincott Williams and Wilkins,Ed.KE Hoover.Such carriers, excipients, or stabilizers can enhance one or more properties of the active ingredients in the compositions described herein, such as biological activity, stability, bioavailability, and other pharmacokinetics and / or biological activity.
[0052] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, benzoate, sorbate, and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, or immunoglobulins. The surfactant may include proteins such as riboflavin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, serine, alanine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextran; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™ (polysorbates), PLURONICS™ (non-ionic surfactants), or polyethylene glycol (PEG).
[0053] In some examples, the pharmaceutical compositions described herein may contain any of the following: trichloromono-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane, chloropenta-fluoroethane, monochloro-difluoroethane, difluoroethane, tetrafluoroethane, heptafluoropropane, octafluoro-cyclobutane, purified water, ethanol, propylene glycol, glycerin, PEG (e.g., PEG400, PEG600, PEG800, and PEG1000), sorbitan trioleate, soy lecithin, lecithin, oleic acid, polysorbate 80, magnesium stearate and sodium lauryl sulfate, methylparaben, proline. Excipients that may include, but are not limited to, paraben, chlorobutanol, benzalkonium chloride, cetylpyridinium chloride, thymol, ascorbic acid, sodium bisulfite, sodium metabisulfite, EDTA, sodium hydroxide, tromethamine, ammonia, HCl, H2SO4, HNO3, citric acid, CaCl2, CaCO3, sodium citrate, sodium chloride, disodium EDTA, saccharin, menthol, ascorbic acid, glycine, lysine, gelatin, povidone K25, silicon dioxide, titanium dioxide, zinc oxide, lactose, lactose monohydrate, lactose anhydrous, mannitol, and dextrose.
[0054] In other examples, the pharmaceutical compositions described herein can be formulated in sustained release form.Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers in the form of shaped articles, such as films or microcapsules.Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and 7-ethyl-L-glutamate, non-degradable ethylene vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.
[0055] Pharmaceutical compositions used for in vivo administration must be sterile. This is easily accomplished, for example, by filtration through sterile filtration membranes. Therapeutic compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle, or a manually accessed sealed container.
[0056] The pharmaceutical compositions described herein may be in unit dosage form, e.g., a solid, solution or suspension, or a suppository, for administration by inhalation or insufflation, by intrathecal, intrapulmonary, or intracerebral routes, oral, parenteral, or rectal administration.
[0057] To prepare solid compositions, the main active ingredient can be mixed with pharmaceutical carriers, such as conventional tableting ingredients, such as cornstarch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a homogeneous mixture of the compound of the present disclosure or a non-toxic pharma-ceutically acceptable salt thereof.When these preformulation compositions are referred to as homogeneous, this means that the active ingredient is evenly distributed throughout the composition, and thus the composition can be easily subdivided into equally effective unit dosage forms, such as powder collections, tablets, pills, and capsules.These solid preformulation compositions are then subdivided into the above-mentioned types of unit dosage forms that contain a suitable amount of active ingredient in the composition.
[0058] Suitable surfactants include, inter alia, non-ionic agents such as polyoxyethylene sorbitan (e.g., TWEEN® 20, 40, 60, 80, or 85) and other sorbitans (e.g., SPAN® 20, 40, 60, 80, or 85). Compositions having a surfactant conveniently contain 0.05 to 5% surfactant, for example 0.1 to 2.5% surfactant. It will be appreciated that other ingredients, such as mannitol or other pharma- ceutically acceptable vehicles, may be added as required.
[0059] Suitable emulsions can be prepared using commercially available fat emulsions, such as INTRALIPIDS™, LIPOSYN™, INFONUTROL™, LIPOFUNDIN™, and LIPIPHYSAN™. The active ingredient may be dissolved in a premixed emulsion composition, or alternatively, the active ingredient may be dissolved in oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil, or almond oil) and in an emulsion formed when mixed with phospholipids (e.g., egg phospholipids, soybean phospholipids, or soybean lecithin) and water. It will be appreciated that other ingredients, such as glycerol or glucose, may be added to adjust the osmolality of the emulsion. Suitable emulsions typically contain up to 20% oil, e.g., 5-20% oil.
[0060] Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In some embodiments, the compositions are composed of particles ranging in size from 10 nm to 100 mm.
[0061] Compositions in pharma- ceutically acceptable solvents, preferably sterile, can be nebulized by the use of gases. Nebulized solutions can be breathed directly from the nebulizing device, or the nebulizing device can be attached to a face mask, tent, endotracheal tube, and / or intermittent positive pressure breathing machine (ventilator). Solution, suspension, or powder compositions can be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
[0062] In some embodiments, any of the modified siRNA molecules can be encapsulated or attached to liposomes, which can be prepared by methods known in the art, such as those described in Epstein, et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985), Hwang, et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980), and U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be produced by reverse phase evaporation with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters with defined pore size to obtain liposomes with desired diameter.
[0063] In some embodiments, any of the modified siRNA molecules can also be encapsulated in microcapsules, such as hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, prepared by coacervation techniques or by interfacial polymerization, respectively, in colloid drug delivery systems (such as liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are known in the art, see, for example, Remington, The Science and Practice of Pharmacy 20th Ed.Mack Publishing (2000).
[0064] Any of the pharmaceutical compositions comprising the modified siRNA molecules disclosed herein may further comprise a component that enhances transport of the composition from endosomes and / or lysosomes to the cytoplasm. Examples include pH-sensitive agents (e.g., pH-sensitive peptides).
[0065] In some embodiments, any of the pharmaceutical compositions herein may further comprise a second therapeutic agent, based on the intended therapeutic use of the composition.
[0066] IV. Inhibition of Target Gene Expression Any of the modified siRNA molecules disclosed herein can be used to silence expression of a target gene either in vivo or in vitro.
[0067] To carry out the methods disclosed herein, an effective amount of the pharmaceutical composition described herein, including modified siRNA molecules, can be administered to a subject (e.g., human) in need of treatment via a suitable route, for example, intravenous administration, for example, as a bolus, or by continuous infusion over a period of time by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarticular, intrasynovial, intratracheal, intratumoral, oral, inhalation, or topical routes. Commercially available nebulizers for liquid formulations, including jet nebulizers and ultrasonic nebulizers, are useful for administration. Liquid formulations can be directly nebulized, and lyophilized powders can be nebulized after reconstitution.
[0068] As used herein, "effective amount" refers to the amount of each active agent required to provide a therapeutic effect to a subject, either alone or in combination with one or more other active agents. Effective amounts will vary, as recognized by those skilled in the art, depending on the specific condition being treated, the severity of the condition, individual patient parameters including age, health, size, sex, and weight, duration of treatment, the nature of concurrent therapy (if any), the specific route of administration, and similar factors within the knowledge and expertise of medical practitioners. These factors are well known to those skilled in the art and can be addressed with only routine experimentation. In general, it is preferred to use the maximum dose of each component or combination thereof, i.e., the highest safe dose according to sound medical judgment.
[0069] Empirical considerations such as half-life generally contribute to the determination of dosage.Dosage frequency can be determined and adjusted over the course of therapy, generally, but not necessarily, based on the treatment and / or suppression and / or remission and / or delay of target disease / disorder.Alternatively, modified siRNA sustained continuous release formulations may be appropriate.Various formulations and devices for achieving sustained release are known in the art.
[0070] In general, for administration of any of the modified siRNA molecules described herein, the initial candidate dosage may be about 2 mg / kg. For purposes of this disclosure, a typical daily dosage may range anywhere from about 0.1 μg / kg to 3 μg / kg to 30 μg / kg to 300 μg / kg to 3 mg / kg to 30 mg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administration over several days or more, depending on the condition, treatment is continued until a desired suppression of symptoms occurs or until a sufficient therapeutic level is achieved to alleviate the target disease or disorder or its symptoms. An exemplary dosing regimen includes administering an initial dose of about 2 mg / kg, followed by a weekly maintenance dose of about 1 mg / kg of anti-siRNA, or followed by a biweekly maintenance dose of about 1 mg / kg. However, other dosing regimens may be useful depending on the pattern of pharmacokinetic decay the practitioner wishes to achieve. For example, administration 1 to 4 times per week is contemplated. In some embodiments, a dose ranging from about 3 μg / mg to about 2 mg / kg (e.g., about 3 μg / mg, about 10 μg / mg, about 30 μg / mg, about 100 μg / mg, about 300 μg / mg, about 1 mg / kg, and about 2 mg / kg) may be used. In some embodiments, the dosing frequency is once every week, every 2 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, or every 10 weeks, or once every month, every 2 months, or every 3 months or more. The progress of this therapy is easily monitored by conventional techniques and assays. Dosage regimens may vary over time.
[0071] In some embodiments, for a normal weight adult patient, a dose ranging from about 0.3 to 5.00 mg / kg may be administered. The particular dosing regimen, i.e., dose, timing, and repetition, will depend on the particular individual and that individual's medical history, as well as the characteristics of the individual drug (e.g., drug half-life, and other considerations well known in the art).
[0072] For the purposes of this disclosure, the appropriate dosage of modified siRNA described herein depends on the type and severity of the disease / disorder, whether the modified siRNA is administered for prevention or treatment, previous therapy, the patient's clinical history and the patient's response to the antagonist, and the discretion of the attending physician. The clinician may administer modified siRNA molecules until a dosage is reached that achieves the desired result. In some embodiments, the desired result is a reduction in tumor burden, a reduction in cancer cells, or an increase in immune activity.
[0073] The method of determining whether the dosage has produced the desired result is clear to those skilled in the art.The administration of one or more modified siRNA molecules can be continuous or intermittent, for example, depending on the physiological state of the recipient, whether the purpose of administration is therapeutic or preventive, and other factors known to the skilled practitioner.The administration of the modified siRNA molecules disclosed herein can be essentially continuous over a preselected period of time, or can be a series of spaced doses, for example, either before, during, or after the onset of the target disease or disorder.
[0074] As used herein, the term "treating" refers to the application or administration of a composition comprising one or more active agents to a subject having a target disease or disorder, a symptom of a disease / disorder, or a predisposition to a disease / disorder, for the purpose of curing, curing, alleviating, mitigating, altering, remediating, ameliorating, improving, or affecting the disorder, the symptom of the disease, or the predisposition to the disease or disorder.
[0075] Alleviating the target disease / disorder includes delaying the onset or progression of the disease or reducing disease severity. Alleviating the disease does not necessarily require a curative outcome. As used herein, "delaying" the onset of the target disease or disorder means to postpone, prevent, slow, retard, stabilize, and / or prolong the progression of the disease. This delay can be of various lengths of time, depending on the disease history and / or the individual being treated. A method of "delaying" or alleviating the onset of a disease or delaying the onset of a disease is a method that reduces the probability of developing one or more symptoms of the disease within a given time frame and / or reduces the severity of symptoms within a given time frame when compared to not using the method. Such comparisons are typically based on clinical studies using a sufficient number of subjects to obtain statistically significant results.
[0076] "Onset" or "progression" of a disease refers to early signs and / or subsequent progression of the disease. Onset of a disease can be detectable and can be evaluated using standard clinical techniques well known in the art. However, onset also refers to progression, which can be undetectable. For purposes of this disclosure, onset or progression refers to the biological course of a symptom. "Onset" includes onset, recurrence, and onset. As used herein, "onset" or "onset" of a target disease or disorder includes initial onset and / or recurrence.
[0077] Conventional methods known to those skilled in the medical arts can be used to administer the pharmaceutical composition to a subject, depending on the type of disease or site of disease being treated. The composition can also be administered via other conventional routes, for example, orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, intravaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intratumoral, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. In addition, the composition can be administered to a subject via an injectable depot administration route, for example, using 1, 3, or 6 month depot injectable or biodegradable materials and methods. In some embodiments, the composition can be administered via the nasal route, for example, via intranasal spray, nasal spray, or nasal drops.
[0078] Injectable compositions may contain various carriers, such as vegetable oils, dimethylactamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols, such as glycerol, propylene glycol, and liquid polyethylene glycol. For intravenous injection, modified siRNAs can be administered by drip infusion, whereby a pharmaceutical formulation containing interfering RNA and a physiologically acceptable excipient is injected. Physiologically acceptable excipients can include, for example, 5% dextrose, 0.9% saline, Ringer's solution, or other suitable excipients. For intramuscular preparations, for example, a sterile formulation of a suitable soluble salt form of modified siRNA disclosed herein can be administered dissolved in a pharmaceutical excipient, such as water for injection, 0.9% saline, or 5% glucose solution.
[0079] In one embodiment, modified siRNA molecule can be administered by site-specific or targeted local delivery technique.Examples of site-specific or targeted local delivery technique include various implanted depot sources of therapeutic RNA molecules or local delivery catheters, such as injection catheters, indwelling catheters or needle catheters, synthetic grafts, adventitial wraps, shunts and stents or other implanted devices, site-specific carriers, direct injection or direct application.See, for example, WO 00 / 53211 and US Patent No. 5,981,568.
[0080] Targeted delivery of therapeutic compositions containing polynucleotides, expression vectors, or subgenomic polynucleotides can also be used. Receptor-mediated DNA delivery techniques are described, for example, in Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (JA Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. USA (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338.
[0081] In some embodiments, any of the modified siRNA molecules or pharmaceutical compositions comprising same can be administered by pulmonary delivery system, i.e., the active pharmaceutical ingredient is administered into the lungs.The pulmonary delivery system can be an inhaler system.In some embodiments, the inhaler system is a pressurized metered dose inhaler, a dry powder inhaler, or a nebulizer.In some embodiments, the inhaler system is with a spacer.
[0082] In some embodiments, the pressurized metered dose inhaler comprises a propellant, a co-solvent, and / or a surfactant. In some embodiments, the propellant is selected from the group comprising fluorinated hydrocarbons, such as trichloromono-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane, chloropenta-fluoroethane, monochloro-difluoroethane, difluoroethane, tetrafluoroethane, heptafluoropropane, octafluoro-cyclobutane. In some embodiments, the co-solvent is selected from the group comprising purified water, ethanol, propylene glycol, glycerin, PEG400, PEG600, PEG800, and PEG1000. In some embodiments, the surfactant or lubricant is selected from the group comprising sorbitan trioleate, soy lecithin, lecithin, oleic acid, polysorbate 80, magnesium stearate, and sodium lauryl sulfate. In some embodiments, the preservative or antioxidant is selected from the group including methylparaben, propyparaben, chlorobutanol, benzalkonium chloride, cetylpyridinium chloride, thymol, ascorbic acid, sodium bisulfite, sodium metabisulfite, sodium hydrogen sulfate, EDTA. In some embodiments, the pH or tonicity adjustment is selected from the group including sodium oxide, tromethamine, ammonia, HCl, H2SO4, HNO3, citric acid, CaCl2, CaCO3.
[0083] In some embodiments, the dry powder inhaler comprises a dispersant, hi some embodiments, the dispersant or carrier particles are selected from the group including lactose, lactose monohydrate, lactose anhydrous, mannitol, dextrose, and have a particle size of about 1-100 μm.
[0084] In some embodiments, the nebulizer may include a co-solvent, a surfactant, a lubricant, a preservative, and / or an antioxidant. In some embodiments, the co-solvent is selected from the group including purified water, ethanol, propylene glycol, glycerin, PEG (e.g., PEG400, PEG600, PEG800, and / or PEG1000). In some examples, the surfactant or lubricant is selected from the group including sorbitan trioleate, soy lecithin, lecithin, oleic acid, magnesium stearate, and sodium lauryl sulfate. In some examples, the preservative or antioxidant is selected from the group including methylparaben, propyparaben, chlorobutanol, benzalkonium chloride, cetylpyridinium chloride, thymol, ascorbic acid, sodium bisulfite, sodium metabisulfite, sodium bisulfate, and EDTA. In some examples, the nebulizer further comprises a pH adjuster or an osmolarity adjuster selected from the group including sodium oxide, tromethamine, ammonia, HCl, H2SO4, HNO3, citric acid, CaCl2, CaCO3.
[0085] In some embodiments, DNA molecules capable of producing anti-HIF1a interfering RNA, or pharmaceutical compositions containing such, may be used to silence HIF1a expression. Pharmaceutical compositions containing such DNA molecules (e.g., vectors) may be administered to a subject in need of treatment in the range of about 100 ng to about 200 mg of DNA for local administration in gene therapy protocols. In some embodiments, concentration ranges of about 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg or more of DNA may also be used in gene therapy protocols.
[0086] In some embodiments, a DNA molecule capable of producing anti-SARS-CoV interfering RNA, or a pharmaceutical composition comprising the same, may be used to silence SARS-CoV2 genes. A pharmaceutical composition comprising such a DNA molecule (e.g., a vector) may be administered to a subject in need of treatment in the range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. In some embodiments, concentration ranges of about 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg or more of DNA may also be used during a gene therapy protocol.
[0087] The term "about" or "approximately" as used herein means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within an acceptable standard deviation, according to practice in the art. Alternatively, "about" can mean a range of up to ±20%, preferably up to ±10%, more preferably up to ±5%, and even more preferably up to ±1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 2-fold, of a value. When a particular value is described in the present specification and claims, unless otherwise stated, the term "about" is implicit and in this context means within an acceptable error range for the particular value.
[0088] The subject treated by any of the modified siRNA molecules may have or be suspected of having a disease associated with the target gene, the inhibition of which may be achieved by the modified siRNA molecules (see target genes disclosed above). The terms "subject", "individual" and "patient" are used interchangeably herein and refer to a mammal being evaluated for treatment and / or being treated. The subject may be a human, but also includes other mammals, particularly mammals useful as experimental models for human disease, such as mice, rats, rabbits, dogs, monkeys, etc. The human subject in need of treatment may be a human patient having, at risk of, or suspected of having a target disease / disorder, such as a tumor.
[0089] Any of the modified siRNA molecules disclosed herein can be used to treat disease or disorder associated with the target gene.Exemplary diseases include, but are not limited to, cancer, fibrosis, metabolic disease, cardiovascular disease, immune disease, or genetic disorder.
[0090] Any of the modified interfering RNAs disclosed herein can be used to treat diseases or disorders associated with the gene targeted by the interfering RNA. Examples include, but are not limited to, solid tumors, cancer, ischemic heart disease, congestive heart failure, acute lung injury, pulmonary hypertension, pulmonary fibrosis, chronic obstructive pulmonary disease, acute liver failure, liver fibrosis and cirrhosis, acute kidney injury, chronic kidney disease, obesity, and diabetes.
[0091] Any of the modified siRNAs disclosed herein may be used in combination therapy with one or more additional therapeutic agents to treat a target disease. As used herein, the term combination therapy includes administration of these agents (e.g., modified siRNA molecules and additional therapeutic agents) in a sequential manner, i.e., each therapeutic agent is administered at a different time, and administration of at least two of these therapeutic agents or agents in a substantially simultaneous manner. The sequential or substantially simultaneous administration of each agent may be effected by any suitable route, including, but not limited to, oral, intravenous, intramuscular, intratumoral, subcutaneous, direct absorption through mucosal tissue, and pulmonary delivery route. The agents may be administered by the same route or by different routes. For example, a first agent may be administered by a pulmonary delivery route, and a second agent may be administered intravenously.
[0092] As used herein, the term "sequential" means that, unless otherwise specified, the agents are characterized by a regular order or sequence, e.g., if a dosing regimen includes administration of a composition and an antiviral agent, a sequential dosing regimen may include administering the composition before, at the same time, substantially at the same time, or after administration of the antiviral agent, but both agents are administered in a regular order or sequence. The term "separate" means spaced apart from one another, unless otherwise specified. The term "concurrently" means occurring or taking place at the same time, i.e., the agents of the present invention are administered at the same time, unless otherwise specified. The term "substantially simultaneously" means that the agents are administered within minutes of each other (e.g., within 10 minutes of each other), and is intended to encompass both conjoint administration and sequential administration, but when administration is sequential, the administration is separated in time by only a short period of time (e.g., the time it takes a medical professional to administer two compounds separately). As used herein, simultaneous administration and substantially simultaneous administration are used interchangeably. Sequential administration refers to the administration of the agents described herein separated in time.
[0093] Combination therapy can also include administering the agents described herein in further combination with other biologically active ingredients and non-pharmaceutical therapies. It is understood that any combination of the compositions described herein with a second therapeutic agent can be used in any order to treat the target disease.
[0094] Efficacy of treatment for a target disease / disorder can be assessed by methods well known in the art.
[0095] In some embodiments, any of the modified siRNAs may be used to silence expression of a target gene in vitro. To carry out such a method, the modified siRNA (e.g., via an encoding nucleic acid such as a vector) may be contacted with cells cultured in vitro for research purposes, such as, for example, studying disease mechanisms and / or validating drug candidates.
[0096] V.Kit The present disclosure may be used alone or as a component of a kit having at least one of the reagents necessary to perform in vitro or in vivo introduction of siRNA for testing samples and / or subjects.
[0097] For example, preferred components of the kit include the modified siRNA molecules of the present disclosure and a vehicle that facilitates introduction of the siRNA into a cell of interest as described herein (e.g., using lipid and other transfection methods known in the art, see, e.g., Beigelman et al., U.S. Patent No. 6,395,713).
[0098] The kits may also be used for determining gene function and / or activity, or for target validation in drug optimization, drug discovery, and the like (see, e.g., Usman et al., U.S. Application No. 60 / 402,996). Such kits may also include instructions that enable a user of the kit to practice the present disclosure. Such kits may optionally include one or more of the second therapeutic agents also described herein.
[0099] In some embodiments, the kit can include instructions for use with any of the methods described herein. The kit can further include instructions for selecting an individual suitable for treatment based on identifying the individual as having or at risk for a disease.
[0100] The instruction for using modified siRNA molecule to achieve intended therapeutic effect generally includes information on dosage, administration schedule and administration route for intended treatment.Container can be unit dose, bulk package (e.g., multi-dose package), or sub-unit dose.The instruction provided in the kit of the present disclosure is typically written instruction on label or package insert (e.g., paper sheet included in the kit), but machine-readable instruction (e.g., instruction carried on magnetic or optical memory disk or QR code) is also acceptable.
[0101] The label or package insert may indicate that the composition is used for its intended therapeutic utility. Instructions for practicing any of the methods described herein may be provided.
[0102] The kit of the present disclosure is in suitable packaging. Suitable packaging includes, but is not limited to, chambers, vials, bottles, jars, and flexible packaging (e.g., sealed Mylar or plastic bags), etc. Also contemplated are packages for use in combination with certain devices, such as inhalers, nebulizers, ventilators, nasal administration devices (e.g., atomizers), or injection devices, such as mini-pumps. The kit may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle). The container may also have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle).
[0103] The kit may optionally provide additional components such as buffers and interpretive information. Typically, the kit comprises a container and a label or package insert on or associated with the container. In some embodiments, the disclosure provides an article of manufacture comprising the contents of the kit described above.
[0104] Common techniques The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of those in the art. Such techniques are described in Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press, Oligonucleotide Synthesis (MJ Gait, ed. 1984), Methods in Molecular Biology, Humana Press, Cell Biology: A Laboratory Notebook (JECellis, ed., 1989) Academic Press, Animal Cell Culture (RIFreshney, ed. 1987), Introuction to Cell and Tissue Culture (JP Mather and PE Roberts, 1998) Plenum Press, Cell and Tissue Culture: Laboratory Procedures (A. Doyle, JBGriffiths, and DG Newell, eds. 1993-8) J. Wiley and Sons, Methods in Enzymology (Academic Press, Inc.), Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.): Gene Transfer Vectors for Mammalian Cells (JMMiller and MP Calos, eds., 1987), Current Protocols in Molecular Biology (FMAusubel, et al. eds. 1987), PCR: The Polymerase Chain Reaction, (Mullis, et al., eds. 1994), Current Protocols in Immunology (JEColigan et al., eds., (1991), Short Protocols in Molecular Biology (Wiley and Sons, 1999), Immunobiology (C.A. Janeway and P. Travers, 1997), Antibodies (P. Finch, 1997), Antibodies: a practice approach (D. Catty., ed., IRL Press, 1988 - 1989), Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000), Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999), The Antibodies (M. Zanetti and J.D. Capra, eds. Harwood Academic Publishers, 1995), DNA Cloning: A practical Approach, Volumes I and II (D.N. Glover ed. 1985), Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. (1985>>, Transcription and Translation (B.D. Hames & S.J. Higgins, eds. (1984>>, Animal Cell Culture (R.I. Freshney, ed. (1986>>, Immobilized Cells and Enzymes (lRL Press, (1986>>, and are fully described in the literature such as B. Perbal, A practical Guide To Molecular Cloning (1984), F.M. Ausubel et al. (eds.).
[0105] Without further elaboration, it is believed that one skilled in the art can utilize the present disclosure to its fullest extent based on the above description. Accordingly, the following specific embodiments are to be construed as merely illustrative, and not limiting of the remainder of the disclosure in any way. All publications mentioned herein are incorporated by reference for the purpose or subject matter referred to herein.
[0106] Example 1: Chemically modified siRNA targeting HIF1A and its interference efficiency To identify a chemical modification pattern of siRNA that provides superior interference efficiency of the target gene (HIF-1A in this example), two anti-HIF-1A siRNAs, AI3 and AT9, were modified in the manners shown in Tables 1 and 2 below, respectively. [Table 1-1] [Table 1-2] [Table 2-1] [Table 2-2]
[0107] Twenty modified siRNAs for each of AI3 and AT9 listed in Tables 1 and 2 were investigated for their activity in inhibiting target gene expression. Each of the modified siRNAs and the unmodified control were transfected into human hepatocellular carcinoma (HepG2) cells at a concentration of 10 nM. 24 hours after transfection, HIF-1A mRNA levels in the transfected cells were detected via RT-qPCR. HIF-1A mRNA expression levels (%) in the transfected cells were calculated using the HIF-1A mRNA levels in the non-transfected cells as 100%. The results are provided in Tables 1-2 above.
[0108] A brief description of the assay method is provided below. Cultivation of HepG2 cells Human hepatocellular carcinoma (HepG2) cell line was maintained in minimum essential medium (Gibco, ThermoFisher Scientific, USA) containing 10% fetal bovine serum (Gibco, ThermoFisher Scientific), 200 units / mL penicillin + 200 units / mL streptomycin at 37°C and 5% CO2.
[0109] siRNA transfection in HepG2 cells HepG2 cells were cultured in a 24-well culture plate at 5 × 10 5 Cells / well were seeded. After 18 hours of incubation, the medium was replaced with 500ul of fresh growth medium. The siRNA and RNAiMax complex composition for each well was prepared as follows: (1) 1ul of siRNA was added to 50ul of Opti-MEM, (2) 1.5ul of RNAiMax was added to 50ul of Opti-MEM, and (3) (1) and (2) were mixed gently and incubated at room temperature for 10 minutes. Transfection was performed by adding 100ul of siRNA / RNAiMax complex to each well. The cells were then incubated for 24 hours before RNA purification.
[0110] RT-qPCR Total RNA was extracted with the RNeasy kit (Qiagen) according to the manufacturer's protocol. HIF1A mRNA levels were quantified using one-step real-time quantitative PCR with the iTaq Universal Probes One-Step Kit (Bio-Rad) run on a LightCycler 480 (Roche Diagnostics). RT-qPCR was run in triplicate in a 384-well plate with 50 ng total RNA, 500 nM of each forward primer, reverse primer and probe, 0.25 ul of reverse transcriptase, and 2× iTaq Master Mix in a total volume of 10 ul. Primers and probes for HIF1A and GAPDH (Table 4) were synthesized from Integrated DNA Technologies. Cycling conditions followed the manufacturer's recommended cycling parameters: 50°C for 10 min, 95°C for 2 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Gene expression fold changes were calculated using the ΔΔCt method. HIF1A mRNA was normalized to constitutively expressed GAPDH mRNA.
[0111] As listed in Table 3, additional modification patterns of AI3 siRNA and AT9 siRNA were further designed and screened in HepG2 cells. [Table 3-1] [Table 3-2] [Table 3-3] [Table 4]
[0112] Table 3 shows the corresponding HIF1A expression levels in cells transfected with each of the identified siRNAs at a concentration of 0.5 nM. Four modification patterns for anti-HIF-1A AI3 siRNAs were identified from in vitro screening studies of chemical modifications as having similar or higher interference efficiency to unmodified AI3. Modified AI3 siRNAs with these modification patterns include AI3-G4S, AI3-G8S, AI3-G8A, and AI3-G25S. Similarly, four modified AT9 siRNAs were identified from in vitro screening assays as having similar interference efficiency to unmodified AT9. Examples include AT9-G1S, AT9-G1A, AT9-G8S, and AT9-G31A.
[0113] Example 2: Chemically modified siRNA targeting SARS-CoV-2 and its interference efficiency To further identify and validate additional chemical modification patterns of siRNAs with desired biological characteristics, two siRNAs, C6 and C8, targeting the genomic and subgenomic mRNAs of the SARS-CoV-2 virus, were modified with the patterns listed in Table 5. [Table 5-1] [Table 5-2]
[0114] Each of the modified siRNAs targeting SARS-CoV-2 and the unmodified counterparts were transfected into Vero E6 cells. Briefly, Vero cells were reverse transfected with the siRNA candidates and then seeded into 24-well culture plates. 24 hours after transfection, the siRNA-transfected cells were infected with SARS-CoV-2 virus at an MOI of 0.1. After 1 hour of incubation, the inoculum was removed and the cells were washed with phosphate-buffered saline (PBS). Fresh medium was added and incubation was continued for 24 hours. After 24 hours of incubation, knockdown of SARS-CoV-2 RNA genome by siRNA in Vero E6 cells was determined by RT-qPCR targeting the E (envelope) gene.
[0115] Total cellular RNA was extracted with NucleoSpin RNA mini kit (Macherey-Nagel, Duren, Germany). The amount of viral RNA was determined by reverse transcription quantitative polymerase chain reaction (RT-qPCR) of the viral E gene using the iTaq Universal Probes One-Step RT-PCR Kit (Bio-Rad) on a QuantStudio 5 Real-Time PCR System (Applied Biosystems). Primers and probes targeting SARS-CoV-2 were as follows: forward primer, 5'-ACAGGTACGTTAATAGTTAATAGCGT-3' (SEQ ID NO: 143), reverse primer, 5'-ACATTGCAGCAGTACGCACACA-3' (SEQ ID NO: 144), and probe, 5'-ACACTAGCCATCCTTACTGCGCTTCG-3' (SEQ ID NO: 145). A plasmid containing a partial E fragment was used as a standard to calculate the viral load (copies / μl).
[0116] Five modification patterns were identified for C6 and C8 siRNAs that maintained good silencing efficiency compared to unmodified siRNAs at a concentration of 20 nM for each siRNA. The following modified siRNAs included five modification patterns: C6-G8A, C6-G22A, C6-G25S, C6-G1A, and C6-G31A.
[0117] As shown in Table 6, phosphorothioate (PS) internucleotide linkages at the ends of siRNAs to protect the siRNAs from nuclease degradation do not affect the interference efficiency of the siRNAs. [Table 6]
[0118] Example 3: Chemically modified siRNA with 5'-phosphate modifications targeting HBx transcripts and their interference efficiency To investigate whether 5' phosphate modification can improve the interference efficiency of siRNA with the chemical modification pattern disclosed herein, the 5' end of the antisense strand of an exemplary siRNA targeting a highly conserved sequence in the X open reading frame (HBx) of all Hepatitis B virus transcripts was further modified with E-vinyl phosphonate or phosphorothioate.The sequence and modification of an exemplary anti-HBx siRNA are shown in Table 7.The chemical structures of 5'-phosphate modified E-vinyl phosphonate and phosphorothioate are shown in Figure 2A. [Table 7]
[0119] The human hepatocellular carcinoma cell line Hep3B was maintained in DMEM medium (Gibco, ThermoFisher Scientific, USA) containing 10% fetal bovine serum (Gibco, ThermoFisher Scientific) at 37°C and 5% CO2.
[0120] Hep3B cells, 4 × 10 4Cells / well were seeded into 24-well culture plates. After 18 hours of incubation, Hep3B cells were transfected with each of the modified anti-HBx siRNAs following the same approach as previously described in relation to HepG2 cells. See Example 2 above. Cells were then incubated for 24 hours and total RNA was extracted from the siRNA-transfected Hep3B cells using the RNeasy kit (Qiagen). Reverse transcription reactions were performed using the Maxima First-Strand cDNA Synthesis kit (Thermo Fisher Scientific) and 100 ng of extracted total cellular RNA. qPCR was performed on a LightCycler 480 using SYBR Green I Master (Roche Diagnostics) with a 1:5 dilution of cDNA. The primer sets used to detect HBx transcripts are shown in Table 8. Each sample was assayed in triplicate to determine the mean threshold cycle (Ct) value. Gene expression fold changes were calculated using the △△Ct method. The mRNA levels of each gene were normalized to constitutively expressed GAPDH mRNA, used as a housekeeping control. [Table 8]
[0121] The human hepatocellular carcinoma cell line Hep3B cells contain an integrated hepatitis B virus genome and can therefore express HBx transcripts. Anti-HBx siRNA with or without 5' phosphate modification (10 or 1.2 nM siRNA) was transfected into Hep3B cells for 24 hours, and HBx was detected. X The expression of the transcripts was quantified by RT-qPCR. As shown in Figure 2B, HBx siRNA with E-vinylphosphonate (X32-G25S-PS6-VP) or phosphorothioate (X32-G25S-PS6-5S) 5'-phosphate modifications improved the siRNA interference efficiency of reducing the expression of HBx transcripts compared with the HBx siRNA counterpart (X32-G25S-PS6) without 5'-phosphate modifications.
[0122] Other embodiments All of the features disclosed herein may be combined in any combination. Each feature disclosed herein may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar functionality.
[0123] From the above description, those skilled in the art can easily ascertain the essential features of the present disclosure, and can make various changes and modifications to the present disclosure to adapt the present invention to various uses and conditions without departing from the spirit and scope of the present invention. Accordingly, other embodiments are also within the scope of the claims.
[0124] Equivalent While several inventive embodiments have been described and illustrated herein, various other means and / or structures for performing the functions described herein and / or obtaining one or more of the results and / or advantages described herein will readily occur to those skilled in the art, and each such variation and / or modification is intended to be within the scope of the inventive embodiments described herein. In general, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications in which the inventive teachings are used. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific inventive embodiments described herein. Thus, it is understood that the above-described embodiments are presented by way of example only, and that within the scope of the appended claims and their equivalents, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods is included within the inventive scope of the present disclosure, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent.
[0125] As defined and used herein, all definitions should be understood to take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.
[0126] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may include the entire document.
[0127] As used in the specification and claims, the indefinite articles "a" and "an" should be understood to mean "at least one," unless clearly indicated to the contrary.
[0128] As used in the present specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so conjoined, i.e., the elements are present conjunctively in some cases and non-conjunctively in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements are so conjoined. Other elements other than the elements specifically identified by the "and / or" phrase may optionally be present, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), and so forth.
[0129] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" is interpreted as being inclusive, i.e., including at least one of, but also including two or more of, some elements or lists of elements, and optionally including additional items not listed. Only terms clearly indicated to the contrary, e.g., "only one of," or "exactly one of," or when used in the claims, "consisting of" refers to including exactly one element of, some elements or lists of elements. In general, as used herein, the term "or" is only interpreted as indicating exclusive alternatives (i.e., "one or the other, but not both") when preceded by a term of exclusivity, e.g., "either," "one of," "only one of," or "exactly one of." When used in the claims, "consisting essentially of" has its ordinary meaning as used in the field of patent law.
[0130] As used in this specification and claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for elements other than the elements specifically identified in the list of elements and referred to by the phrase "at least one," whether related or unrelated to the elements specifically identified, may optionally be present. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer to, in one embodiment, at least one, optionally, two or more As, and no B (optionally including elements other than B); in another embodiment, at least one, optionally, two or more Bs, and no A (optionally including elements other than A); in yet another embodiment, at least one, optionally, two or more As, and at least one, optionally, two or more Bs (optionally including other elements); etc.
[0131] Also, unless expressly stated to the contrary, in any method claimed herein that includes two or more steps or actions, it should be understood that the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are recited.
Claims
1. A modified small interfering RNA (siRNA) comprising a sense strand having 19 nucleotides and an antisense strand having 21 nucleotides, (a) the antisense strand contains (i) from 7 to 9 2'-fluoro modified nucleotides, and (ii) from 12 to 14 2'-O-methyl modified nucleotides; (b) the sense strand contains (i) from 2 to 5 2'-fluoro modified nucleotides, and (ii) from 11 to 16 2'-O-methyl modified nucleotides; the sense strand, the antisense strand, or both, contain one or more phosphothioate (PS) linkages; A modified small interfering RNA (siRNA), wherein the sense strand and the antisense strand form a double-stranded siRNA, optionally with a 2-nucleotide overhang at the 3' end of the antisense strand.
2. The modified siRNA of claim 1, wherein the antisense strand contains a modified 5'-phosphate.
3. The modified siRNA of claim 2, wherein the modified 5'-phosphate is an E-vinylphosphonate or a phosphorothioate.
4. The modified siRNA of any one of claims 1 to 3, wherein the antisense strand contains the 2'-fluoro modified nucleotides at 7 or more of positions 2-12, 14-16, and 18.
5. The modified siRNA of claim 4, wherein the antisense strand comprises 2'-fluoro modified nucleotides at positions 2 or 3, and 14, and optionally 18.
6. The modified siRNA according to any one of claims 1 to 5, wherein in (a), the antisense strand contains the 2'-O-methyl modified nucleotides at 12 or more of positions 1, 2 to 13, and 15 to 21.
7. The modified siRNA of claim 6, wherein the antisense strand comprises 2'-O-methyl modified nucleotides at positions 1, 13, 17, and 19-21.
8. The modified siRNA according to any one of claims 1 to 7, wherein in (b), the sense strand contains the 2'-fluoro modified nucleotide at two or more of positions 5 and 7 to 11.
9. The modified siRNA of claim 8, wherein the sense strand comprises 2'-fluoro modified nucleotides at positions 5 and 7-10, or at positions 5, 7, 9, and 11.
10. The modified siRNA of any one of claims 1 to 9, wherein the sense strand contains the 2'-O-methyl modified nucleotides at 11 or more of positions 1 to 6, 8, and 10 to 19.
11. The modified siRNA of claim 10, wherein the sense strand comprises 2'-O-methyl modified nucleotides at positions 4, 6, and 11-19.
12. The modified siRNA of claim 11, wherein the sense strand further comprises 2'-O-methyl modified nucleotides at positions 8 and 10.
13. The modified siRNA of any one of claims 10 to 12, wherein one or more of positions 1 to 3 in the sense strand contain a 2'-O-methyl modified nucleotide.
14. The modified siRNA of any one of claims 10 to 12, wherein one or more of positions 1 to 3 in the sense strand are unmodified.
15. The modified siRNA of any one of claims 1 to 14, wherein the sense strand contains a 2'-deoxynucleotide, the 2'-deoxynucleotide optionally being located at position 9.
16. The modified siRNA of any one of claims 1 to 15, wherein the antisense strand contains a PS bond between positions 1 and 2, between positions 2 and 3, between positions 19 and 20, and / or between positions 20 and 21.
17. 17. The modified siRNA of claim 1, wherein the sense strand contains a PS bond between positions 1 and 2, between positions 2 and 3, between positions 4 and 5, between positions 5 and 6, between positions 17 and 18, and / or between positions 18 and 19.
18. The antisense strand of (a) and the sense strand of (b) have the following formula: (i) 5'-mffmmffmmffmmffmmfmmm-3' 3'-mmmmmmmmmmmmdffmmmmmm-5', (ii) 5'-mmfmfmfmfmmmmfmfmfmmm-3' 3'-mmmmmmmmmmmmffffmfmmmm-5', (iii) 5'-mmfmfmfmfmmmmfmfmfmmm-3' 3'-mmmmmmmmmmmmffffmfmrrr-5', (iv) 5'-mfmfmfmffmmmmfmfmfmmm-3' 3'-mmmmmmmmmmmmffffmfmrrr-5' (v) 5'-mfmffmmffmmmmfmfmfmmm-3' 3'-mmmmmmmmmmmmffffmfmmmm-5', (vi) 5'-mfmfmfmfmfmfmfmfmfmmm-3' 3'-mmmmmmmmmmfmfmfmfmmmm-5', (vii) 5'-mfmfmfmfmfmfmfmfmfmmm-3' 3'-mmmmmmmmfmfmfmfmrrr-5'' or (viii) 5'-mfmfmfmfmfmfmfmfmmmmmm-3' 3'-mmmmmmmmfmfmfmfmrrr-3', 2. The modified siRNA of claim 1, wherein m represents a 2'-O-methyl nucleotide, f represents a 2'-fluoro nucleotide, r represents an unmodified nucleotide, and d represents a DNA residue.
19. The antisense strand of (a) and the sense strand of (b) have the following formula: (i) 5'-m*f*fmmffmmffmmffmmfm*m*m-3' 3'-m*m*mmmmmmmmmmdffmmmm*m*m-5', (ii) 5'-m*m*fmfmfmfmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffmfmm*m*m-5', (iii) 5'-m*m*fmfmfmfmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffm*f*mrrr-5', (iv) 5'-m*f*mfmfmffmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffm*f*mrrr-5' (v) 5'-m*f*mffmmffmmmmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmffffmfmm*m*m-5', (vi) 5'-m*f*mfmfmfmfmfmfmfmfm*m*m-3' 3'-m*m*mmmmmmmmfmfmfmfmm*m*m-5', (vii) 5'-m*f*mfmfmfmfmfmfmfmfm*m*m-3' 3'-m*m*mmmmmmfmfmfm*f*mrrr-5'' or (viii) 5'-m*f*mfmfmfmfmfmfmfmmm*m*m-3' 3'-m*m*mmmmmmfmfmfm*f*mrrr-3', 19. The modified siRNA of claim 18, wherein m represents a 2'-O-methyl nucleotide, f represents a 2'-fluoro nucleotide, r represents an unmodified nucleotide, d represents a DNA residue, and * represents a PS bond.
20. The modified siRNA of any one of claims 1 to 19, wherein the sense strand is conjugated to a targeting moiety, the targeting moiety optionally being N-acetylgalactosamine (GalNAc).
21. A pharmaceutical composition comprising the siRNA according to any one of claims 1 to 20 and a pharma- ceutically acceptable carrier.
22. 22. A method for regulating gene expression, comprising contacting a cell with an siRNA according to any one of claims 1 to 20, or a pharmaceutical composition according to claim 21, wherein the siRNA targets a gene of interest.
23. The method of claim 22, wherein the contacting step is carried out by administering the siRNA or the pharmaceutical composition to a subject having a disease associated with the gene of interest.
Citation Information
Patent Citations
Small molecule complexes for intracellular delivery of nucleic acids
JP2014504499A
Hepatitis B virus (HBV) iRNA composition and method of using the same
JP2017538679A
Compositions and methods for inhibiting gene expression of hif2α
JP2018516595A
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
WO2020123410A1
Rnai agents for hepatitis b virus infection
WO2020163747A1
